KR100486016B1 - 타크로리무스의 속용성 고체분산체 및 이의 제조방법 - Google Patents
타크로리무스의 속용성 고체분산체 및 이의 제조방법 Download PDFInfo
- Publication number
- KR100486016B1 KR100486016B1 KR10-2004-0053269A KR20040053269A KR100486016B1 KR 100486016 B1 KR100486016 B1 KR 100486016B1 KR 20040053269 A KR20040053269 A KR 20040053269A KR 100486016 B1 KR100486016 B1 KR 100486016B1
- Authority
- KR
- South Korea
- Prior art keywords
- solid dispersion
- tacrolimus
- solid
- carrier
- surfactant
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
- A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Transplantation (AREA)
- Communicable Diseases (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims (7)
- 타크로리무스 약물과 담체로서 HLB 값이 7 이상이고 실온에서 고형인 계면활성제로 구성됨을 특징으로 하는 고체분산체.
- 제 1 항에 있어서, 계면활성제가 HLB값이 40인 라우릴황산나트륨, HLB값이 7 이상인 폴록사머류 또는 HLB값이 7 내지 18의 수크로스지방산에스테르 중에서 단독 또는 2종 이상 선택됨을 특징으로 하는 고체분산체.
- 제 1 항에 있어서, 타크로리무스 약물과 계면활성제의 중량비가 1 : 0.1 내지 1 : 100의 범위인 고체분산체.
- 제 1 항 내지 제 3 항 중 어느 한 항에 있어서, 고체분산체의 담체기능을 갖지 않는 제약상 허용되는 부형제, 붕해제, 착색제, 착향제, 감미제, 활택제 중에서 선택되는 1 종 이상의 첨가제를 더 포함함을 특징으로 하는 고체분산체.
- 타크로리무스와 HLB 값이 7 이상이고 실온에서 고형인 계면활성제를 에탄올, 이소프로필알콜, 디클로로메탄 또는 클로로포름 중에서 단독으로 또는 2종 이상을 혼합한 용매에 함께 용해 또는 분산시키는 단계를 포함하여 타크로리무스 고체분산체를 건조하는 것을 특징으로 하는 고체분산체의 제조방법.
- 제 5 항에 있어서, 고체분산체의 담체기능을 갖지 않는 제약상 허용되는 부형제, 붕해제, 착색제, 착향제, 감미제, 활택제 중에서 선택되는 1 종 이상의 첨가제를 더 포함함을 특징으로 하는 고체분산체의 제조방법.
- 타크로리무스와 HLB 값이 7 이상이고 실온에서 고형인 계면활성제를 에탄올, 이소프로필알콜, 디클로로메탄 또는 클로로포름 중에서 단독으로 또는 2종 이상을 혼합한 용매에 함께 용해 또는 분산시킨 용액을 제약상 허용되는 부형제, 붕해제, 착색제, 착향제, 감미제, 활택제 중에서 선택되는 1 종 이상의 첨가제에 분무하여 과립화하는 것을 특징으로 하는 고체분산체의 제조방법.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20030046550 | 2003-07-09 | ||
KR1020030046550 | 2003-07-09 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20050007173A KR20050007173A (ko) | 2005-01-17 |
KR100486016B1 true KR100486016B1 (ko) | 2005-04-29 |
Family
ID=36587202
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR10-2004-0053269A KR100486016B1 (ko) | 2003-07-09 | 2004-07-09 | 타크로리무스의 속용성 고체분산체 및 이의 제조방법 |
Country Status (9)
Country | Link |
---|---|
US (1) | US20060177500A1 (ko) |
EP (1) | EP1641437A4 (ko) |
JP (1) | JP2007527383A (ko) |
KR (1) | KR100486016B1 (ko) |
CN (1) | CN1819817A (ko) |
BR (1) | BRPI0412329A (ko) |
MX (1) | MXPA06000370A (ko) |
NO (1) | NO20060631L (ko) |
WO (1) | WO2005004848A1 (ko) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100693461B1 (ko) * | 2005-07-29 | 2007-03-12 | 동국제약 주식회사 | 마크로라이드계 항생물질을 유효성분으로 함유하는약제학적 조성물 및 이의 제조방법과, 상기 약제학적조성물을 함유하는 서방성 제제 |
KR100711220B1 (ko) * | 2005-06-14 | 2007-04-24 | 삼천당제약주식회사 | 타크로리무스를 함유하는 경구용 조성물 및 그의 제조방법 |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK1663217T3 (da) * | 2003-08-29 | 2010-11-08 | Lifecycle Pharma As | Faste dispersioner indeholdende tacrolimus |
EP1663216B1 (en) | 2003-08-29 | 2011-11-02 | Veloxis Pharmaceuticals A/S | Modified release compositions comprising tacrolimus |
KR100539706B1 (ko) * | 2005-01-25 | 2005-12-28 | 지엘팜텍 주식회사 | 타크로리무스 및 장용성 고분자를 함유하는 고체분산체 |
KR100678824B1 (ko) * | 2005-02-04 | 2007-02-05 | 한미약품 주식회사 | 용해성이 증가된 무정형 타크로리무스 고체분산체 및 이를포함하는 약제학적 조성물 |
MXPA05010457A (es) * | 2005-09-28 | 2007-03-27 | Fernando Ahumada Ayala | Preparacion para el tratamiento de enfermedades inflamatorias de la piel, que contiene tacrolimus. |
DE102005047561A1 (de) * | 2005-10-04 | 2007-04-05 | Bayer Healthcare Ag | Feste, oral applizierbare pharmazeutische Darreichungsformen mit schneller Wirkstofffreisetzung |
WO2008033023A2 (en) * | 2006-09-15 | 2008-03-20 | Echo Pharmaceuticals B.V. | Granulate containing a pharmaceutically active substance and anemulsifier and method for its manufacture |
WO2008033024A2 (en) | 2006-09-15 | 2008-03-20 | Echo Pharmaceuticals B.V. | Dosage unit for sublingual, buccal or oral administration of water-insoluble pharmaceutically active substances |
WO2008041553A1 (fr) * | 2006-09-26 | 2008-04-10 | Astellas Pharma Inc. | Préparation à libération entretenue de tacrolimus |
WO2008127746A1 (en) | 2007-01-10 | 2008-10-23 | Board Of Regents The University Of Texas System | Enhanced delivery of immunosuppressive drug compositions for pulmonary delivery |
CA2688381C (en) | 2007-05-30 | 2016-10-11 | Lifecycle Pharma A/S | Once daily oral dosage form comprising tacrolimus |
EP2400950B1 (en) | 2009-02-26 | 2019-05-22 | Glaxo Group Limited | Pharmaceutical formulations comprising 4-{(1 r)-2-[(6-{2-[(2,6-dichlorobenzyl)oxy]ethoxy}hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl)phenol |
GB0921075D0 (en) | 2009-12-01 | 2010-01-13 | Glaxo Group Ltd | Novel combination of the therapeutic agents |
PT2575769T (pt) | 2010-02-17 | 2016-09-22 | Veloxis Pharmaceuticals As | Composição de tacrolímus estabilizada |
KR20130028824A (ko) * | 2011-09-09 | 2013-03-20 | 주식회사 삼양바이오팜 | 타크로리무스를 포함하는 고체 분산체 및 이의 제조방법 |
JP2015521175A (ja) | 2012-05-07 | 2015-07-27 | エコ・ファーマシューティカルズ・ビー.ブイ.Echo Pharmaceuticals B.V. | カンナビノイド含有粒状体、その製造方法、及びこのような粒状体を含む経口投与単位 |
CN104415054A (zh) * | 2013-08-20 | 2015-03-18 | 哈药集团三精制药股份有限公司 | 一种速释复方氨酚烷胺片的制备方法 |
CN110639020B (zh) * | 2019-08-15 | 2022-07-08 | 浙江工业大学 | 一种固体分散体基质及其制备方法和应用 |
CN113577032A (zh) * | 2021-08-27 | 2021-11-02 | 国药集团川抗制药有限公司 | 他克莫司固体分散体的制备方法、速释药物组合物和应用 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4894366A (en) * | 1984-12-03 | 1990-01-16 | Fujisawa Pharmaceutical Company, Ltd. | Tricyclo compounds, a process for their production and a pharmaceutical composition containing the same |
GB8608080D0 (en) * | 1986-04-02 | 1986-05-08 | Fujisawa Pharmaceutical Co | Solid dispersion composition |
FR2736550B1 (fr) * | 1995-07-14 | 1998-07-24 | Sandoz Sa | Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule |
CZ267796A3 (cs) * | 1996-09-12 | 1998-04-15 | Galena A.S. | Léčivé přípravky, zejména pro vnitřní aplikaci, ve formě samomikroemulgujících terapeutických systémů |
ZA9710927B (en) * | 1996-12-06 | 1998-06-15 | Fujisawa Pharmaceutical Co | Pharmaceutical composition. |
EP0978288A4 (en) * | 1997-04-11 | 2006-07-12 | Astellas Pharma Inc | DRUG COMPOSITION |
WO1999049863A1 (fr) * | 1998-03-26 | 1999-10-07 | Fujisawa Pharmaceutical Co., Ltd. | Preparations a liberation prolongee |
US6248363B1 (en) * | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
US20010036959A1 (en) * | 2000-04-03 | 2001-11-01 | Gabel Rolf Dieter | Carvedilol-hydrophilic solutions |
EP1663216B1 (en) * | 2003-08-29 | 2011-11-02 | Veloxis Pharmaceuticals A/S | Modified release compositions comprising tacrolimus |
-
2004
- 2004-07-09 JP JP2006518554A patent/JP2007527383A/ja active Pending
- 2004-07-09 MX MXPA06000370A patent/MXPA06000370A/es unknown
- 2004-07-09 WO PCT/KR2004/001684 patent/WO2005004848A1/en active Application Filing
- 2004-07-09 US US10/563,972 patent/US20060177500A1/en not_active Abandoned
- 2004-07-09 KR KR10-2004-0053269A patent/KR100486016B1/ko active IP Right Grant
- 2004-07-09 CN CNA2004800193916A patent/CN1819817A/zh active Pending
- 2004-07-09 EP EP04774097A patent/EP1641437A4/en not_active Withdrawn
- 2004-07-09 BR BRPI0412329-8A patent/BRPI0412329A/pt not_active IP Right Cessation
-
2006
- 2006-02-09 NO NO20060631A patent/NO20060631L/no not_active Application Discontinuation
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100711220B1 (ko) * | 2005-06-14 | 2007-04-24 | 삼천당제약주식회사 | 타크로리무스를 함유하는 경구용 조성물 및 그의 제조방법 |
KR100693461B1 (ko) * | 2005-07-29 | 2007-03-12 | 동국제약 주식회사 | 마크로라이드계 항생물질을 유효성분으로 함유하는약제학적 조성물 및 이의 제조방법과, 상기 약제학적조성물을 함유하는 서방성 제제 |
Also Published As
Publication number | Publication date |
---|---|
WO2005004848A1 (en) | 2005-01-20 |
NO20060631L (no) | 2006-04-05 |
BRPI0412329A (pt) | 2006-09-05 |
MXPA06000370A (es) | 2006-03-28 |
EP1641437A4 (en) | 2009-06-03 |
KR20050007173A (ko) | 2005-01-17 |
EP1641437A1 (en) | 2006-04-05 |
JP2007527383A (ja) | 2007-09-27 |
US20060177500A1 (en) | 2006-08-10 |
CN1819817A (zh) | 2006-08-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100486016B1 (ko) | 타크로리무스의 속용성 고체분산체 및 이의 제조방법 | |
US11129815B2 (en) | Solid dispersions comprising tacrolimus | |
KR100440553B1 (ko) | 서방성 제제 | |
KR100626785B1 (ko) | 콜로이드성 이산화규소를 포함하는 제약 조성물 | |
US8591946B2 (en) | Modified release compositions comprising tacrolimus | |
JP4825223B2 (ja) | 溶解性が増加した非晶質タクロリムス固体分散体及びこれを含む医薬組成物 | |
KR100546047B1 (ko) | 디히드로피리딘계 화합물의 서방출성 제제 및 그 제조방법 | |
EP4026541A1 (en) | A film coated tablet of apixaban | |
KR100485876B1 (ko) | 펠로디핀-함유 서방성 정제의 제조방법 | |
KR100711220B1 (ko) | 타크로리무스를 함유하는 경구용 조성물 및 그의 제조방법 | |
MXPA06002246A (es) | Dispersiones solidas que comprenden tacrolimus |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
A302 | Request for accelerated examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20130402 Year of fee payment: 9 |
|
FPAY | Annual fee payment |
Payment date: 20140318 Year of fee payment: 10 |
|
FPAY | Annual fee payment |
Payment date: 20160303 Year of fee payment: 12 |
|
FPAY | Annual fee payment |
Payment date: 20170320 Year of fee payment: 13 |
|
FPAY | Annual fee payment |
Payment date: 20180212 Year of fee payment: 14 |
|
FPAY | Annual fee payment |
Payment date: 20190325 Year of fee payment: 15 |